Rizatriptan Efficacy in ICHD‐II Pure Menstrual Migraine and Menstrually Related Migraine

Nett, Robert; Mannix, Lisa K.; Mueller, Loretta; Rodgers, Anthony; Hustad, Carolyn M.; Skobieranda, Franck; Ramsey, Karen E.

doi:10.1111/j.1526-4610.2008.01093.x

Cited by 28 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Again, women in the rizatriptan group experienced a significant improvement in 2-hour pain relief compared with the placebo group. Nett et al [18] reanalyzed the Mannix data, comparing 2-hour migraine relief in the PMM group to the MRM group. They found a similar response to rizatriptan in both groups.…”

Section: Abortive Therapiesmentioning

confidence: 99%

Management of Menstrual Migraine: A Review of Current Abortive and Prophylactic Therapies

Sullivan

Bushnell

2010

Curr Pain Headache Rep

View full text Add to dashboard Cite

After menarche, women have an increased prevalence of migraine compared to men. There is significant variability in the frequency and severity of migraine throughout the menstrual cycle. Women report migraines occur more frequently during menses, and that those are more severe than other migraines. This creates a unique challenge of effectively treating menstrually related and pure menstrual migraines. As with treatment of other migraines, both abortive and prophylactic treatment regimens are used. Triptans demonstrate efficacy in the abortive management of menstrually related and pure menstrual migraines. For migraines that occur primarily during menses or that are particularly resistant to other therapies, intermittent prophylactic therapies can be used. Naproxen and estrogens have been studied for this use. More recently, triptans have been examined and have shown efficacy for intermittent prophylaxis of menstrual migraine.

show abstract

Section: Abortive Therapiesmentioning

confidence: 99%

Management of Menstrual Migraine: A Review of Current Abortive and Prophylactic Therapies

Sullivan

Bushnell

2010

Curr Pain Headache Rep

View full text Add to dashboard Cite

show abstract

“…Rizatriptan 10 mg was effective for the treatment of ICHD-II menstrual migraine in two prospective, randomised, double-blind, placebocontrolled trials, as measured by 2 hour pain relief and 24 hour sustained pain relief in 707 women [Nett et al 2008]. In an early intervention model using rizatriptan 10 mg, 2 hour pain-free rates were comparable for 94 women treating menstrual and nonmenstrual migraine attacks [Martin et al 2008].…”

Section: Therapeutic Advances In Neurological Disorders 2 (5)mentioning

confidence: 99%

Review: Menstrual migraine: therapeutic approaches

MacGregor

2009

Ther Adv Neurol Disord

View full text Add to dashboard Cite

The development of diagnostic criteria has enabled greater recognition of menstrual migraine as a highly prevalent and disabling condition meriting specific treatment. Although few therapeutic trials have yet been undertaken in accordance with the criteria, the results of those published to date confirm the efficacy of acute migraine drugs for symptomatic treatment. If this approach is insufficient, the predictability of attacks provides the opportunity for perimenstrual prophylaxis. Continuous contraceptive strategies provide an additional option for management, although clinical trial data are limited. Future approaches to treatment could explore the genomic and nongenomic actions of sex steroids.

show abstract

“…[5] performed a rizatriptan effi cacy study that was a prospectively planned substudy of pooled data from a study by Mannix et al [6] of ICHD-II-proposed MM. This report [6] of two identical randomized, doubleblind, placebo-controlled trials (RDBPCTs) was listed in this journal by Allais et al [1•] in table form in 2007.…”

Section: Clinical Aspectsmentioning

confidence: 99%

Clinical aspects of perimenstrual headaches

Taylor

2009

Current Science Inc

View full text Add to dashboard Cite

Menstrual migraine (MM) is either pure, if attacks are limited solely during the perimenstrual window (PMW), or menstrually related (MRM), if two of three PMWs are associated with attacks with additional migraine events outside the PMW. Acute migraine specific therapy is equally effective in MM and non-MM. Although the International Classification of Headache Disorders-II classifies MM without aura, data suggest this needs revision. The studies on extended-cycle oral contraceptives suggest benefits for headache-prone individuals. Triptan mini-prophylaxis outcomes are positive, but a conclusion of "minimal net benefit compared to placebo" is not entirely unwarranted. In a 2008 evidence-based review, grade B recommendations exist for sumatriptan (50 and 100 mg), mefenamic acid (500 mg), and riza-triptan (10 mg) for the acute treatment of MRM. For the preventive mini-prophylactic treatment of MRM, grade B recommendations are provided for transcutaneous estrogen (1.5 mg), frovatriptan (2.5 mg twice daily), and naratriptan (1 mg twice daily).

show abstract

Rizatriptan Efficacy in ICHD‐II Pure Menstrual Migraine and Menstrually Related Migraine

Abstract: Rizatriptan 10 mg was superior to placebo for the treatment of PMM, as measured by 2-hour pain relief. Rizatriptan was also effective for the treatment of MRM and for relief of migraine-associated symptoms for both headache subtypes.

Cited by 28 publications

References 14 publications

Management of Menstrual Migraine: A Review of Current Abortive and Prophylactic Therapies

Management of Menstrual Migraine: A Review of Current Abortive and Prophylactic Therapies

Review: Menstrual migraine: therapeutic approaches

Clinical aspects of perimenstrual headaches

Contact Info

Product

Resources

About